LOADING

Type to search

Immunomedics Taps Ipsen’s Harout Semerjian as President and CEO

BioTech

Immunomedics Taps Ipsen’s Harout Semerjian as President and CEO

Share
immunomedics-taps-ipsen’s-harout-semerjian-as-president-and-ceo

Xconomy
New York
— 

Immunomedics (NASDAQ: IMMU) has appointed Harout Semerjian to serve as its president and CEO. Semerjian is joining the Morris Plains, NJ-based cancer drug developer from Ipsen, where he is executive vice president and chief commercial officer. His experience also includes positions at Novartis (NYSE: NVS). Semerjian will start at Immunomedics on April 16. An FDA decision on sacituzumab govitecan, an Immunomedics drug developed for triple-negative breast cancer, is expected by June 2.

Frank Vinluan is an Xconomy editor based in Research Triangle Park. You can reach him at fvinluan@xconomy.com. Follow @frankvinluan

Trending on Xconomy

Tags:

You Might also Like

Leave a Comment

Your email address will not be published. Required fields are marked *